DxS is a personalised medicine company providing cancer mutation products, technologies and genetic analysis services to enable the delivery of safe and effective medicines. DxS has developed a range of tumour analysis products that detect mutations in EGFR, RAS, RAF and other genes associated with cancer drug responses.